Skip to content
DataLookout
Menu

NCT03793517

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

StatusUnknown
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2020); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

1 year cumulative incidence of relapse
Timeframe: 1 year post allo-HSCT
2 year cumulative incidence of relapse
Timeframe: 2 years post allo-HSCT

Secondary (8)

Non-relapse mortality
1 year overall survival
5 years overall survival
1 year leukemia free survival
5 years leukemia free survival
Show 3 moreShow less
engraftment
Acute graft versus host disease
Chronic graft versus host disease

Arms and interventions

Decitabine plus mBU/CY for HLA-mismatched HSCTExperimental

Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT. Details: The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2.

Decitabine plus mBU/CY for matched sibling transplantExperimental

Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant. Details: In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3.

Drugs: Decitabine, mBU/CY and ATG, mBU/CY

Sites

1 site in 1 country

  • Peking University Institute of Hematology,BeijingBeijing, Beijing Municipality, China